Attovia Therapeutics, a Fremont, CA-based developer of a pipeline of biotherapeutics with an preliminary concentrate on immune-mediated ailments, raised $105m in Sequence B financing.
The spherical, which introduced the whole quantity to $165m, was led by Goldman Sachs Alternate options, with participation from new buyers Cormorant Asset Administration, Nextech Ventures, Redmile Group, EcoR1 Capital, Marshall Wace, Logos Capital and present buyers Frazier Life Sciences, venBio, and Illumina Ventures. Concurrent with the financing, Colin Walsh, Ph.D., Managing Director inside Life Sciences Investing at Goldman Sachs Alternate options, was appointed to the Board of Administrators.
The corporate intends to us the funds to advance its lead applications ATTO-1310 and ATTO-002 by preliminary medical knowledge readouts, broaden its immunology and irritation pipeline, and to additional develop the ATTOBODY™ platform.
Led by CEO Tao Fu, Attovia is making a pipeline of biotherapeutics with an preliminary concentrate on immune-mediated ailments. The corporate leverages ATTOBODY™, a biparatopic biologics platform, to generate binders that provide stronger efficacy and a broader universe of druggable epitopes in comparison with conventional approaches. The lead applications, ATTO-1310, a possible first-in-class, lengthy half-life anti-IL31 ATTOBODY, and ATTO-002, a bispecific anti-IL31 x IL13 ATTOBODY, signify potential best-in-class therapeutics for a spread of immune-mediated ailments. ATTO-1310 is presently in IND enabling research and is on monitor to enter the clinic round year-end 2024 for the therapy of atopic dermatitis and different pruritic ailments. Attovia expects to appoint a improvement candidate for ATTO-002 within the second half of 2024 and advance the candidate to IND in 2025. The corporate can be creating discovery stage applications that broaden the ATTOBODY platform footprint to novel, difficult-to-drug targets, and provide extra multi-specific mixtures.
Commenting on the information, Tao Fu mentioned: “We’re grateful for the help from such a robust group of buyers, permitting us to advance our lead applications to the clinic within the close to time period, additional broaden our pipeline in novel bi-specifics, and catalyze potential enterprise improvement alternatives.”
FinSMEs
10/05/2024
